首页> 美国卫生研究院文献>BMC Cardiovascular Disorders >A genetic variant c.553G  T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug
【2h】

A genetic variant c.553G  T (rs2075291) in the apolipoprotein A5 gene is associated with altered triglycerides levels in coronary artery disease (CAD) patients with lipid lowering drug

机译:载脂蛋白A5基因的遗传变异c.553G T(rs2075291)与冠心病(降脂药)患者的甘油三酸酯水平改变有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

BackgroundElevated plasma triglycerides (TGs) are widely used as a major cardiovascular risk predictor and are thought to play an important role in the progression of coronary heart disease (CHD). It has been demonstrated that lipid lowering was associated with lower mortality in patients with CHD. The present study therefore aimed to investigate the consequences of the genetic variant c.553G > T (rs2075291) in apolipoprotein A5 gene to determination of triglycerides levels in CAD patients receiving, atorvastatin, lipid lowering drug.
机译:背景技术血浆甘油三酸酯(TGs)升高被广泛用作心血管疾病的主要预测指标,并被认为在冠心病(CHD)的进展中起着重要作用。已经证实,降低血脂与降低冠心病患者的死亡率有关。因此,本研究旨在调查载脂蛋白A5基因中遗传变异c.553G> T(rs2075291)对确定接受阿托伐他汀,降脂药物的CAD患者中甘油三酸酯水平的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号